Business Wire

CA-TALKDESK

21.2.2024 15:01:30 CET | Business Wire | Press release

Share
Talkdesk Hires Software Veteran Albert Caravelli to Lead, Grow Strategic Alliances and Partners

Talkdesk®, Inc., a global AI-powered contact center leader for enterprises of all sizes, today announced that Albert (Al) Caravelli, an accomplished executive experienced in transforming sales and alliances organizations at some of the world’s leading software companies, has joined the company as senior vice president of Alliances and Partners.

In this role, Caravelli is responsible for expanding and nurturing Talkdesk’s growing ecosystem of strategic technology alliance partners, global system integrators, and global service providers.

Caravelli comes to Talkdesk following nearly nine years at cloud security company Zscaler, where he most recently served as global vice president of strategic alliances and advisory firms, responsible for leading Zscaler’s go-to-market strategy and execution. During this time, he was instrumental in the formation of strategic alliances with multiple companies, including Accenture, Capgemini, Deloitte, HCL, Infosys, AT&T, BT, Cognizant, Deutsche Telekom, OBS, Telefonica, TCS, TechMahindra, LTIM, Verizon, Vodafone, and Wipro.

Before his tenure at Zscaler, Caravelli served as senior director of worldwide global alliances at HP Software, where he drove the transformation of the global alliances function, resulting in better strategic engagement with partners and new joint offerings. He has also served in alliances leadership at Jive Software and Mercury Interactive and in sales roles at Asera, Nielsen Claritas, and The Nielsen Company. Caravelli started his career as a sales manager at Nestle.

A former international athlete, Caravelli continues to serve as a technical advisor and guest commentator for the HSBC World Rugby Sevens, which supports local rugby unions in preparing and qualifying for the Olympics and other competitions. He was the former head coach for USA Rugby and the Philippines Volcanoes National Teams. Caravelli volunteers with the Special Olympics and Wounded Warriors.

He holds a bachelor’s degree in computer science from the University of California, Los Angeles (UCLA) and a Master of Business Administration (MBA) from the UCLA Anderson School of Management.

Supporting Quotes

Tiago Paiva, founder and chief executive officer of Talkdesk, commented: “In the last year, we have added phenomenal talent to our leadership team. Al brings a wealth of experience to help Talkdesk accelerate its corporate strategy. His expertise in building and guiding exceptional partner and alliance teams will be vital as we execute our vision of reaching $1 billion in revenue, scale globally, and transform the contact center industry.”

Al Caravelli, senior vice president of Strategic Alliances and Partners at Talkdesk, said: “I’ve admired the success of Talkdesk for years. When the opportunity to join the leadership team arose, I was eager to start a conversation. As I spoke with Tiago and others throughout the organization, it was clear that my experience and strategic playbook dovetailed nicely with the company’s business goals. I look forward to getting to know the partner ecosystem and aligning on new strategies and initiatives.”

Rex Thexton, senior managing director at Accenture, stated: “I've had the pleasure of working closely with Al in recent years. I have witnessed first-hand how his experience building and strengthening alliance and partner programs helps companies accelerate their revenue and strategic goals. He will be a tremendous asset to the Talkdesk leadership team.”

Sherry Vaswani, group chief executive officer of Xalient, said: “I've had the opportunity to work first-hand with Al for the last seven years. We’ve called on customers together, and we’ve planned and executed campaigns that led to many joint customer successes. Al helped develop the partnership between Zscaler and Xalient, appreciating the needs that we have at all stages of our expansion and proactively supporting us to achieve significant growth. I know he will add huge value to Talkdesk.”

About Talkdesk

Talkdesk® is a global cloud contact center leader for enterprises of all sizes. Talkdesk CX Cloud and Industry Experience Clouds help enterprises deliver modern customer service their way. Our trusted, flexible, and innovative contact center platform leverages AI and automation to drive exceptional outcomes for their customers and improve the bottom line. Serving enterprise customers in over 100 countries, we partner with our customers to deliver continuous innovation and breakthrough results. Our unwavering commitment to doing what we say we will do, and our investment in the highest levels of security and reliability for our products, make us second to none in the industry. Improve customer experiences, increase efficiency, and grow revenue with Talkdesk, a cloud contact center platform built for your industry. Learn more and take a self-guided demo at www.talkdesk.com.

Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240220064868/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye